The estimated Net Worth of Jesse Michael Bruff is at least $1.18 Millón dollars as of 1 March 2021. Jesse Bruff owns over 6,499 units of Varian Medical Systems stock worth over $13,608 and over the last 5 years Jesse sold VAR stock worth over $1,166,619.
Sign up
Jesse Bruff VAR stock SEC Form 4 insiders trading
Jesse has made over 6 trades of the Varian Medical Systems stock since 2020, according to the Form 4 filled with the SEC. Most recently Jesse sold 6,499 units of VAR stock worth $1,142,589 on 1 March 2021.
The largest trade Jesse's ever made was exercising 31,053 units of Varian Medical Systems stock on 1 December 2020 worth over $3,847,156. On average, Jesse trades about 5,899 units every 54 days since 2020. As of 1 March 2021 Jesse still owns at least 823 units of Varian Medical Systems stock.
You can see the complete history of Jesse Bruff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Varian Medical Systems
Over the last 21 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin y Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.
What does Varian Medical Systems's logo look like?
Complete history of Jesse Bruff stock trades at Varian Medical Systems
Varian Medical Systems executives and stock owners
Varian Medical Systems executives and other stock owners filed with the SEC include:
-
Dow Wilson,
Chief Executive Officer, Director -
Kolleen Kennedy,
President - Proton Solutions Division and Chief Growth Officer -
Chris Toth,
President, Chief Operating Officer -
R. Andrew Eckert,
Independent Chairman of the Board -
Jeffrey Balser,
Independent Director -
Judy Bruner,
Independent Director -
Anat Ashkenazi,
Independent Director -
Jean-Luc Butel,
Independent Director -
Regina Dugan,
Independent Director -
David Illingworth,
Independent Director -
Phillip Febbo,
Independent Director -
Michael Hutchinson,
Senior Vice President, Chief Legal Officer -
Francis Facchini,
President, Interventional Solutions Business -
Anshul Maheshwari,
Vice President, Treasurer and Investor Relations -
Michelle Le Beau,
Independent Director -
J. Michael Bruff,
Chief Financial Officer, Senior Vice President - Finance -
Magnus Momsen,
SVP, CAO, Corporate Controller -
Mark R Laret,
Director -
Jose Baselga,
Director -
John W Kuo,
SVP, Gen Counsel and Secretary -
Gary E Jr Bischoping,
SVP, Finance & CFO -
Susan L Bostrom,
Director -
Timothy E Guertin,
Director -
Clarence R Verhoef,
SVP, Finance, Corp Controller -
Venkatraman Thyagarajan,
Director -
Sunny Sanyal,
SVP and President, ICB -
Robert H Kluge,
Corporate Vice President -
Richard M Levy,
President and CEO -
Ruediger Naumann Etienne,
Director -
John Seely Brown,
Director -
Erich R Reinhardt,
Director -
Tai Yun Chen,
VP and Corporate Controller -
David W Jr Martin,
Director -
Steven A Leibel,
Director -
Kent J Thiry,
Director -
Allen S Lichter,
Director -
Samuel Hellman,
Director -
Crisanto C Raimundo,
Corporate Controller -
Terry R Lautenbach,
Director -
Joseph B Phair,
VP Admin,Gen Counsel,Secretary -
Elisha W Finney,
Corporate Vice President & CFO -
Kevin O'reilly,
SVP, President of Oncology Sys